Results with ENBREL in Moderately to Severely Active Juvenile Idiopathic Arthritis (JIA)
In 1999, ENBREL became the first biologic medicine approved to treat moderate to severe juvenile idiopathic arthritis (JIA). It is approved for children 2 years and older.
ENBREL is shown to be effective in treating the signs and symptoms of moderately
to severely active juvenile idiopathic arthritis. Results with ENBREL include: reduced pain, morning
stiffness, and joint swelling.
Results for your child may vary. Because ENBREL works on the immune system, it
can lower the ability of the immune system to fight infections and may raise
other safety concerns. There have been some cases of unusual cancers reported in children and teenage patients who started using TNF blockers before 18 years of age. Also, for children, teenagers, and adults taking TNF blockers, including ENBREL, the chances of getting lymphoma or other cancers may increase. Patients with RA and psoriasis may be more likely to get lymphoma.
Patients receiving ENBREL may receive concurrent
vaccinations, except for live vaccines. No data are available on the secondary
transmission of infection by live vaccines in patients receiving ENBREL. Please
see information on vaccinations in FAQs.
It is recommended that juvenile idiopathic arthritis patients, if possible, be brought up-to-date with all immunizations in agreement with current immunization guidelines prior to initiating ENBREL therapy. Patients with a significant exposure to varicella virus should temporarily discontinue ENBREL therapy and be considered for prophylactic treatment with Varicella Zoster Immune Globulin. Be sure to read the Important Safety Information and Medication Guide and talk with your child's rheumatologist.
Please see Prescribing Information, Important Safety Information, and Medication Guide for complete details about ENBREL.